Press Release (OSX.AX)

Osteopore Honoured with Distinction Award in Leadership for Good

Admin — Wed, 31 Jul 2024 04:06:29 +0000

Osteopore Honoured with Distinction Award in Leadership for Good

Admin Wed, 07/31/2024 - 12:06

Osteopore is honoured to receive the Distinction Award in the Leadership for Good category at the 10th anniversary of Brands For Good. This prestigious organization recognizes businesses not only for their commercial success but also for their positive impact on communities and the environment worldwide.

At Osteopore, the mission extends beyond innovation; it’s about transforming lives. As a leader in regenerative medicine, Osteopore's proprietary 3D-printed scaffolds support natural tissue regeneration. This advanced technology offers patients the opportunity to restore their own bone with fewer complications compared to permanent implants. The ongoing commitment to innovation ensures continuous enhancement of patient outcomes and quality of life.

"Osteopore believes that medical technology should deliver sustainable clinical outcomes that improve the quality of life for patients and reduce overall healthcare expenses for all payers.", says Osteopore CEO, Dr. Yujing Lim. This guiding principle drives the efforts and inspires the team to push the boundaries of medical technology.

Heartfelt thanks are extended to the entire Osteopore team—both current and former members—whose dedication and commitment have driven the company's success. Their hard work and passion have been instrumental in Osteopore's journey toward achieving its mission.

Osteopore is excited to continue the journey toward a regenerative future, making a positive impact on patients' lives and contributing to a better world. This recognition from Brands For Good reinforces the commitment to the mission and encourages the team to keep pushing forward.

Goh Khoon Seng, Global Marketing Director Osteopore

Osteopore enters into Orthopaedic research collaboration

KSGoh — Mon, 27 Mar 2023 23:34:17 +0000

Osteopore enters into Orthopaedic research collaboration

KSGoh Tue, 03/28/2023 - 07:34

Osteopore Limited (ASX:OSX), a revenue-generating manufacturer of regenerative implants that empower natural tissue regeneration, is pleased to announce that it has entered into a Research Collaboration with Maastricht University (MU), University Hospital Maastricht (MUMC), and a commercial-stage ortho-biologics company.

The clinical research project will study the treatment of large (> 5cm) posttraumatic bone defects using Osteopore’s custom implant made of Polycaprolactone (PCL) and Tricalcium Phosphate (TCP). Osteopore’s implants will be individually coated in a number of growth factors, including Bone Marrow Aspirate Concentrate (BMAC) and an advanced bone graft biologic.

The implants will be tested against existing techniques, including the ‘gold standard’ bone graft, with scans to be taken at 6-month intervals to measure bone growth. The project is expected to run for up to 48 months, and will also investigate the efficacy of Osteopore’s implant coated in the bone graft biologic, in the case of a bacterial infection. This will determine whether bone growth can be maintained under the influence of a bacterial infection, and could lead to the co-development of a new product line.

The findings from this project will help Osteopore advance its broader Orthopaedics commercial strategy, and potentially assist with future regulatory clearances for our orthopaedic product range.

The collaborative project is co-financed with PPP allowance made available by Health~Holland, Top Sector Life Sciences & Health to stimulate public-private partnerships. Osteopore and its research partners will now work towards confirming a formal research and development program and will update the market as milestones are reached.

Executive Chairman, Mark Leong said; “This is a great early-stage, low capital-intensive research project that has promising potential. The project forms part of the Company’s strategy to develop and launch new products to expand the scope of bone regeneration applications across the entire body.”

Goh Khoon Seng, Global Marketing Director Osteopore

Osteopore bolsters Scientific & Clinical Advisory Panel

KSGoh — Fri, 24 Mar 2023 00:40:42 +0000

Osteopore bolsters Scientific & Clinical Advisory Panel

KSGoh Fri, 03/24/2023 - 08:40

Osteopore Limited (ASX: OSX), a global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to introduce that Dr Rondhir Jithoo, Associate Professor Lim Thiam Chye, and Associate Professor Yeo Tseng Tsai, have joined our Scientific and Clinical Advisory Panel (SCAP).

Osteopore’s SCAP is comprised of renowned scientific and clinical experts in the fields of biomaterials, orthopedic surgery, plastic and reconstructive surgery, maxillofacial surgery, and dentistry. They work collaboratively with the Company to provide strategic advice and support, ensuring that our solutions are at the forefront of medical technology and tailored to meet the needs of healthcare professionals and patients alike.

Adding additional SCAP members underscores our commitment to excellence in research and development, and emphasizes our unwavering dedication to improving patient outcomes. We believe that our SCAP will play an instrumental role in driving the growth and success of Osteopore, and we look forward to working closely with this esteemed group of experts to deliver the best possible solutions to our customers.

Executive Chairman, Mark Leong said: “As a company that prides itself on innovation and excellence, we recognize the importance of collaboration and knowledge-sharing with the brightest minds in the scientific and clinical communities. The formation of our Scientific and Clinical Advisory Panel represents a significant step towards achieving our vision of transforming the way we regenerate tissue. We are honored to have the guidance and support of such esteemed experts and are excited to leverage their expertise to drive the continued success of Osteopore."

New Panel Members include :

Dr Rondhir Jithoo

Consultant Neurosurgeon

The Alfred Hospital, Melbourne, Australia

Mr Ron Jithoo is a highly experienced Neurosurgeon who obtained his medical degree from The University of Natal in South Africa where he graduated with a Dean’s Commendation. He also received the South African Society of Neurosurgeons prize as a registrar. Mr Jithoo is the chair of MAC Mulgrave Private Hospital and the secretary of the Neurosurgery Society of Australasia. He is also on the committee of several hospitals and medical associations and was previously the Deputy Director of Neurosciences at the Epworth Hospital. Mr Jithoo has an extensive interest in cranial and Spinal trauma, and anterior spinal surgery, including surgery for degenerative conditions. His skills have been enhanced through his work at Royal Darwin Hospital.

Associate Professor Lim Thiam Chye

Head & Senior Consultant (Plastic, Reconstructive & Aesthetic Surgery)

National University Hospital, Singapore

Associate Professor Lim Thiam Chye is the Head of the Division of Plastic, Reconstructive, and Aesthetic Surgery at the National University Hospital (Singapore) and Associate Professor at the National University of Singapore. He was also the Chairman AO Cranio-Maxillofacial (CMF) Asia-Pacific board. He holds more than 20 years of surgical experience in the Division of Plastic, Reconstructive, and Aesthetic Surgery at NUH. Associate Professor Lim has a wide range of publications, to date he has more than 66 publications in various medical Journals. Associate Professor Lim’s clinical and research work lies in regenerative medicine for bone, skin, and fat. He is also involved in the development and training of a navigational system for Craniomaxillofacial Surgery.

Associate Professor Yeo Tseng Tsai

Head & Senior Consultant (Neurosurgery)

National University Hospital

Associate Professor Yeo is the Head of the Division of Neurosurgery, the National University Hospital, Singapore. He is also the Medical Director of the Singapore Gamma Knife Centre. After undergoing his undergraduate medical training at the National University of Singapore and completing his National Service in the army from 1986 to 1988, he underwent postgraduate neurosurgery training in Melbourne, Australia, and obtained his exit neurosurgical qualifications (FRACS) in 1994. He then underwent further subspecialty training in stereotactic and functional neurosurgery in Toronto, Canada as well as in Seattle, USA, and Grenoble, France. He has been the recipient of numerous research grants over the years and has published widely in the neurosurgical literature in the domains of stereotactic and functional neurosurgery, neuro-oncology, head injury, and virtual reality neurosurgery.

Goh Khoon Seng, Global Marketing Director Osteopore